Connect with us

Featured

Renewable Innovations, Inc. (RI) RM; the Rise of Nestbuilder.com Corp (OTCMKTS: NBLD)

Published

on

Nestbuilder.com Corp (OTCMKTS: NBLD) is moving quickly up the charts after the Company announced a reverse merger with Renewable Innovations, Inc. (RI), whereby Renewable Innovations will be the surviving Company. Renewable Innovations is a big deal; the Company is an emerging leader in clean, hydrogen fuel cell energy systems and has a deal in place with General Motors to supply the military with clean energy. Renewable Innovations plans to uplist to the Nasdaq as soon as it is eligible. 

Reverse Mergers can be more explosive than biotech’s when the incoming Company has real value but is undiscovered to investors and many RM stocks, we have covered on this website have gone from pennies to dollars. One recent RM runners that stand out is HRBR which went from a few cents (where we first wrote about it) to $3 plus. NBLD is debt free 100% fully reporting OTCQB and a valuable reverse merger candidate. NBLD hit a high of $0.93 on Thursday and closed at $0.80 up 2,200% on the day on 1.9 million shares traded. 

NBLD Friday 4PM Close Update: NBLD rocketed up another 210% on Friday to close at $2.50 per share. The stock hit highs of $3.75 on about $5 million in dollar volume. As we reported NBLD is under heavy accumulation after the Company announced a reverse merger with Renewable Innovations, Inc. (RI), whereby Renewable Innovations will be the surviving Company. Renewable Innovations is a big deal; the Company is an emerging leader in clean, hydrogen fuel cell energy systems and has a deal in place with General Motors to supply the military with clean energy. Renewable Innovations plans to uplist to the Nasdaq as soon as it is eligible. We will be updating on NBLD as soon as anything new happens so make sure you are subscribed to Microcapdaily by entering your email in the box below. 

Subscribe to Our 100% Free Penny Stock Newsletter. We Have Something Big Coming!

Nestbuilder.com Corp (OTCMKTS: NBLD) was incorporated in the State of Nevada on January 10, 2017 as a wholly owned subsidiary of RealBiz Media Group, Inc., a Delaware corporation On July 31, 2018. Prior business was servicing large and small broker accounts in the North America Real Estate Market. The Company had the ability to produce over 15,000 videos per day. They also owned the website LoseTheAgent.com. 

Renewable Innovations, Inc. (RI), goal is to accelerate the growth and opportunities within the renewable economy. The Company’s team of industry leaders brings extensive experience and connections across the Renewable, Hydrogen, and Alternative Energy sectors. Along with its partners, investors, and clients, RI is making major technological advancements with products and solutions to lead the world into a new and exciting carbon-free future. Renewable Innovations, advanced power integration, applications, and solutions are focused on creating a new Hydrogen-powered energy economy including Hydrogen Fuel Cell (HFC) scalable backup and primary power systems, Mobile and transportable HFC-powered EV Rapid Charge systems for the Electric Vehicle market, Advanced Hydrogen transport and refueling vehicles and Greenhouse Grids to power communities. 

Immediately prior to the Merger, there were 6,090,580 shares of our Common Stock issued and outstanding and warrants outstanding to acquire up to an aggregate of 10,135,000 shares of our Common Stock. As a result of the Merger, we issued to the shareholders of Renewable Innovations an aggregate of 2,155,684 shares of our Series A Convertible Preferred Stock, par value $0.0001 per share, each share of which is convertible into 100 shares of our Common Stock, which represents a 93% ownership interest based on our fully-diluted capitalization immediately following the Merger. As a result of the foregoing transactions, we underwent a change of control on December 1, 2022. 

In connection with the closing of the Merger, the following changes to the Board occurred on December 1, 2022 (the “Closing Date”), which will result in a change of a majority of the members of the Board: Thomas M. Grbelja and William McLeod resigned as members of the Board, effective on the Closing Date; Robert L. Mount was appointed as a member of the Board, effective on the Closing Date; Lynn Barney was appointed as a member of the Board, effective 10 days after the mailing of this Information Statement to our shareholders; and Alex Aliksanyan resigned as a member of the Board, effective 10 days after the mailing of this Information Statement to our shareholders. 

Currently General Motors is supplying HYDROTEC fuel cell power cubes to Renewable Innovations of Lindon, Utah to build the Mobile Power Generator. GM will combine its fuel cell hardware and software with Renewable Innovations’ power integration and management systems to create a generator that can provide fast-charging capability for EVs without having to expand the grid or install permanent charging assets in places where there’s only a temporary need for power.  

Multiple development projects involving the MPG are already in process, including a demonstration of the technology as a mobile charging station for EVs funded in part by the Michigan Economic Development Corporation and the U.S. Army Combat Capabilities Development Command Ground Vehicle Systems Center. This version of the MPG is expected to first be demonstrated in mid-2022. 

The California Energy Commission is funding a separate demonstration program of four additional MPGs through its Mobile Renewable Backup Generation systems program to show how hydrogen-based mobile power can help offset the loss of energy during the planned power shutoffs used to mitigate wildfires throughout the state. This demonstration is being led by the Electric Power Research Institute, the preeminent independent, non-profit energy research and development organization, collaborating with stakeholders like GM and Renewable Innovations to ensure the public has safe, reliable, affordable and equitable access to hydrogen-generated electricity.

To Find out the inside Scoop on NBLD Subscribe to Microcapdaily.com Right Now by entering your Email in the box below

NBLD

 

In addition to mobile EV charging, GM and Renewable Innovations have collaborated on the EMPOWER rapid charger. Intended to help retail fuel stations add more affordable DC fast charging capability, the EMPOWER rapid charger will help deploy necessary fast charging without significant investment in nonrecoverable electrical infrastructure upgrades, like larger feed wires, transformers and potentially new substations. 

Palletized Mobile Power Generator System – GM designed a separate, palletized version of the MPG which is now being evaluated by U.S. Army Combat Capabilities Development Command Ground Vehicle Systems Center (GVSC).  GVSC is also exploring how this version of the MPG can power heavy-duty military equipment and camps. This prototype is equivalent in size to a 60-kW generator and produces nearly 70 percent more power than traditional diesel generators. This MPG variant also contains features not typically found on diesel generators, like battery backup and output regulation.   

GM will produce HYDROTEC power cubes at its Fuel Cell Systems Manufacturing joint venture with Honda in Brownstown, Michigan. Renewable Innovations will produce the trailer-based MPG and the larger, modular EMPOWER rapid charger at their facilities in the Salt Lake City metro area. 

Renewable Innovations shareholders will retain ninety-three percent (93%) of the publicly traded entity, which has been renamed Renewable Innovations, Inc. The Company intends to leverage its breakthrough hydrogen fuel cell technology, bringing grid independent, clean, renewable solutions for power generation and sustainability to the market. Plans include expansion into retail power distribution, especially along the US highway system through organic growth and acquisitions. Currently, the company is in production on orders for government and private company projects. Renewable Innovation’s integration technology allows for rapid charging of a vehicle in under 20 minutes, offering a significant time savings over current EV charging portals. Since the hydrogen-fueled systems require no grid infrastructure, they can be provisioned anywhere that rapid, carbon-free power is needed.  

Renewable Innovations, Inc. will continue to trade on the OTCQB marketplace maintained by OTC Markets Group, Inc. under the symbol “NBLD” until such time as FINRA approves the name and symbol change. The Company intends to file for a listing on NASDAQ as soon as it is eligible. 

For More on NBLD Subscribe Right Now!

NBLD is rocketing up the charts after announcing the reverse merger with Renewable Innovations, Inc. (RI), an emerging leader in clean, hydrogen fuel cell energy systems that has deals in place with General Motors to supply the military with clean energy. Renewable Innovations plans to uplist to the Nasdaq as soon as it is eligible. Renewable Innovations new campus features 170,000 sq ft of office, R&D, and manufacturing space. We have covered many reverse mergers on this website including HRBR for pennies per share which went on to run to $3 on the Air Wisconsin Reverse merger. Not since HRBR have we seen a bulletin boards RM with as much potential as this Renewable Innovations. We will be updating on NBLD when more details emerge so make sure you are subscribed to Microcapdaily.

Subscribe to Our 100% Free Penny Stock Newsletter. We Have Something Big Coming!

Disclosure: we hold no position in NBLD either long or short and we have not been compensated for this article

Continue Reading
Click to comment

Leave a Reply

Your email address will not be published. Required fields are marked *

Featured

IceCure Medical’s (NASDAQ: ICCM) ProSense: A 96.8% Success Rate Revolutionizing Breast Cancer Treatment

Published

on

On October 2nd, 2023, IceCure Medical (NASDAQ: ICCM) shares surged by over 50% following exciting news presented at a major medical event, the European Society of Breast Imaging. Their cutting-edge ProSense® System, designed for minimally invasive cryoablation, is marketed and sold worldwide for its cleared indications in the U.S., Europe, and China. More recently they gained approvals in India, and Brazil and have additional distribution through MC Medical to continue expanding in Europe. More importantly, the latest independent study confirms that the technology is a safe & effective outpatient procedure for breast cancer, with 96.8% success rate.

More Background:

Their system has the potential to revolutionize cancer treatment not only for breast cancer, but also for kidney, bone, and lung cancers. To date, the system is marketed and sold worldwide for the indications cleared and approved to date including in the U.S., Europe, and China.

During the event, Dr. Lucía Graña-López, a radiologist specializing in breast and women’s imaging, led an independent study. The study explored cryoablation as a viable alternative to surgery for early-stage breast cancer in patients who preferred a non-surgical route. The results were promising, suggesting that cryoablation could be a successful treatment option, particularly for patients hesitant about traditional surgery.

Subscribe to Microcapdaily.com Right Now by entering your Email in the box below.

Subscribe to Our 100% Free Penny Stock Newsletter. We Have Something Big Coming!

Clinical Study:

The study involved 31 patients with early-stage breast cancer who opted out of surgery, and the outcomes showed that cryoablation was well-tolerated with no major complications. This alternative approach could potentially be a game-changer, especially for breast cancer, which is one of the most prevalent cancers globally. Many patients, particularly older individuals, are seeking less invasive alternatives to surgery, making cryoablation an appealing option.

Dr. Graña-López envisions cryoablation becoming a significant alternative to surgery, particularly for early-stage breast cancer in post-menopausal women. Moreover she believes this technology could reshape how we approach treatment in other indications, particularly for kidney, lung, and thyroid gland cancers.

These results from this independent study are are in line with the ongoing ICE3 study, the largest of its kind in the U.S., set to conclude in early 2024.

We will update you on ICCM when more details emerge, subscribe to Microcapdaily to follow along!

Subscribe to Our 100% Free Penny Stock Newsletter. We Have Something Big Coming!

Disclosure: We have not been compensated for this article/video. MicroCap Daily is not an investment advisor; this article/video does not provide investment advice. Always do your research, make your own investment decisions, or consult with your nearest financial advisor. This article/video is not a solicitation or recommendation to buy, sell, or hold securities. This article/video is our opinion, is meant for informational and educational purposes only, and does not provide investment advice. Past performance is not indicative of future performance.

Picture by marijana1 from Pixabay

Continue Reading

Featured

T2 Biosystems (NASDAQ: TTOO) Breaks Ground: FDA Clearance, Market Trends, and Healthcare Impact

Published

on

Shares of T2 Biosystems (NASDAQ:TTOO) are soaring up over 20% today on the heels of receiving a 510(k) clearance for its T2Biothreat from the FDA. This unique test directly detects six biothreat pathogens from a blood sample.

Spotting Biothreats Faster:

T2Biothreat Panel is a game-changer, being the first and only FDA-approved product that can spot these critical biothreat pathogens simultaneously. T2 Biosystems proudly stands as the first U.S. company to achieve this milestone, reshaping the field of biothreat detection.

Big Investor Sells:

Interestingly while celebrating this achievement, a significant investor, CR Group (CRG), decided to sell off a substantial chunk of shares. This sell-off, totaling 24.81 million shares, took place between Sept. 20 and Sept. 26. The timing of this sell-off alongside the FDA clearance raises some eyebrows.

Subscribe to Microcapdaily.com Right Now by entering your Email in the box below.

Subscribe to Our 100% Free Penny Stock Newsletter. We Have Something Big Coming!

New CDC Guidelines:

Regardless of CR Group selling, there still appears to be a massive opportunity according to many retail investors. Following new CDC guidelines, the U.S. government now mandates that all hospitals in the country must adopt rapid testing protocols to combat the sepsis pandemic by 2026, or risk losing Medicare funding.

Buying opportunity of the year!!! Update
byu/den1183 inTTOOstock

T2 Biosystems stands as the exclusive FDA-cleared product capable of achieving 100% accurate sepsis detection within 3 to 5 hours. Anticipating widespread adoption of T2 instruments in hospitals, the CEO foresees significant revenue generation, potentially reaching $1.3 billion annually, given the mandate.

This development drastically alters the landscape, potentially influencing the stock’s trajectory positively. With the ongoing surge in manufacturing hires and likely acceleration in orders, coupled with potential government contracts or international sales, many beleive T2 Biosystems presents an undervalued opportunity for investors.

What Borrowing Costs Tell Us:

Another interesting indicator to look at is the cost to borrow (CTB) fee. In terms of TTOO’s case, the stock has seen a massive surge in CTB fees, indicating a high demand from short sellers. When compared to the average CTB fee for other stocks, it’s pretty drastic. While this is typically not a very positive sign, retail investors seem to be buzzing with interest, given there also could be a potential short squeeze if enough buying comes in to trap the shorts.

Better News for Patients:

But let’s not forget the real impact and that’s what TTOO can do for patients. @ChengKeki a user from Twitter also shared an article about Butler Memorial Hospital and their approach to Sepsis. The hospital came up with a 2 step approach to expedite patient care.  They’re utilizing the Beckman Coulter automation line to identify changes in a person’s blood cells that might indicate the development of sepsis. Which apparently has only been used in Europe and they’re the first in the US with the technology. Then shortly after, they use T2 Biosystems panels that as you know, quicken the process from 36 hours, to just 3-5 hours.

Catching sepsis quickly is crucial because it’s a life-threatening condition that rapidly progresses throughout your body and can lead to death if not promptly diagnosed and treated. Sepsis occurs when the body responds improperly to an infection, causing widespread inflammation and potentially damages multiple organ systems. Early detection allows for immediate medical intervention.

Conclusion:

T2 Biosystems is hitting major milestones, not only in the market but in improving critical healthcare processes. The company is also a major hit with retail investors and continues to trade an astronomical amount of shares daily, the current average is ~115M shares. The FDA approval and its implications, along with the positive shift in sepsis diagnosis, showcase T2 Biosystems’ growing role in healthcare. Keep an eye on how this progresses—it’s exciting for both investors and patients alike.

We will update you on TTOO when more details emerge, subscribe to Microcapdaily to follow along!

Subscribe to Our 100% Free Penny Stock Newsletter. We Have Something Big Coming!

Picture by jarmoluk from Pixabay

 

Continue Reading

BioPharma

Organogenesis (NASDAQ: ORGO): Latest Developments and Future Growth Prospects

Published

on

Organogenesis Holdings (NASDAQ: ORGO), a top regenerative medicine company dedicated to advanced wound care, surgical, and sports medicine solutions, gains over 30% during intraday trading and after hours combined after their latest release. According to the release, three Medicare Administrative Contractors (MACs) decided to withdraw certain coverage rules that were meant to start on October 1. These rules related to products for treating diabetic foot ulcers (DFU) and venous leg ulcers (VLU).

More Background:

Organogenesis serves a range of clients, from hospitals and wound care centers to doctors’ offices. The MACs’ initial rules, set on August 9, caused concern. They specified that covered products must be particular types of skin substitutes. Unfortunately, this excluded five products from Organogenesis, impacting their financial outlook.

Fast forward, the MACs pulled back these rules just in time, preventing potential harm to Organogenesis. Even before these rules, the company was facing challenges. In the second quarter, revenue was slightly down compared to the same period last year. Despite this, the company is doing better than the previous year in a six-month comparison.

Subscribe to Microcapdaily.com Right Now by entering your Email in the box below.

Subscribe to Our 100% Free Penny Stock Newsletter. We Have Something Big Coming!

Gary S. Gillheeney, Sr., the head of Organogenesis, expressed deep gratitude for the MACs and the Centers for Medicare & Medicaid Services (CMS). He praised their thoughtful consideration of stakeholder concerns and putting patients first. This decision will positively affect the lives of many.

He also thanked the stakeholders, including doctors, patient advocacy groups, and various associations. Their unified support played a vital role in challenging these rules, considering the potential harm they could cause patients. Their advocacy shed light on the possible negative health outcomes and treatment disparities, especially for those with higher rates of diabetes and related conditions. Their collective efforts made a significant difference.

We will update you on ORGO when more details emerge, subscribe to Microcapdaily to follow along!

Subscribe to Our 100% Free Penny Stock Newsletter. We Have Something Big Coming!

Disclosure: We have not been compensated for this article/video. MicroCap Daily is not an investment advisor; this article/video does not provide investment advice. Always do your research, make your own investment decisions, or consult with your nearest financial advisor. This article/video is not a solicitation or recommendation to buy, sell, or hold securities. This article/video is our opinion, is meant for informational and educational purposes only, and does not provide investment advice. Past performance is not indicative of future performance.

Picture by Parentingupstream from Pixabay

Continue Reading

Trending

© All rights reserved.

Sign up now for our 100% FREE Penny Stock Newsletter

Privacy Policy. we will never share your email with anyone.